Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $4.5 million.

  • Niagen Bioscience's Non-Current Assets rose 307.66% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year decrease of 503.71%. This contributed to the annual value of $4.2 million for FY2024, which is 2309.39% down from last year.
  • Latest data reveals that Niagen Bioscience reported Non-Current Assets of $4.5 million as of Q3 2025, which was up 307.66% from $4.8 million recorded in Q2 2025.
  • Niagen Bioscience's Non-Current Assets' 5-year high stood at $8.9 million during Q4 2021, with a 5-year trough of $4.2 million in Q4 2024.
  • In the last 5 years, Niagen Bioscience's Non-Current Assets had a median value of $6.5 million in 2023 and averaged $6.4 million.
  • As far as peak fluctuations go, Niagen Bioscience's Non-Current Assets soared by 4554.49% in 2021, and later plummeted by 3037.13% in 2024.
  • Over the past 5 years, Niagen Bioscience's Non-Current Assets (Quarter) stood at $8.9 million in 2021, then dropped by 16.17% to $7.5 million in 2022, then decreased by 27.5% to $5.4 million in 2023, then decreased by 23.09% to $4.2 million in 2024, then grew by 8.31% to $4.5 million in 2025.
  • Its Non-Current Assets was $4.5 million in Q3 2025, compared to $4.8 million in Q2 2025 and $5.1 million in Q1 2025.